Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 1, 2014, Pages 83-89

  Yan, Jun Hong ^a   Gu, Wan Jie ^b   Pan, Lei ^c  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Efficacy; Meta analysis; Roflumilast; Safety

Indexed keywords

ROFLUMILAST;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINAHL; COCHRANE LIBRARY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMBASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSOMNIA; MEDLINE; META ANALYSIS; MORTALITY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EFFICACY; META-ANALYSIS; ROFLUMILAST; SAFETY;

AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; FORCED EXPIRATORY VOLUME; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

EID: 84892445790     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.04.004     Document Type: Article

References (39)

1. Qaseem A., Wilt T.J., Weinberger S.E., Hanania N.A., Criner G., van der Molen T., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
2. Vestbo J., Hurd S.S., Agusti A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
3. Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012, 379:1341-1351.
4. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412.
5. Dalal A.A., Shah M., Lunacsek O., Hanania N.A. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med 2011, 105:1516-1522.
6. Drummond M.B., Dasenbrook E.C., Pitz M.W., Murphy D.J., Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:2407-2416.
7. Rodrigo G.J., Castro-Rodriguez J.A., Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009, 136:1029-1038.
8. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
9. Kim J.H., Park J.S., Kim K.H., Jeong H.C., Kim E.K., Lee J.H. Inhaled corticosteroid is associated with an increased risk of tuberculosis in patients with chronic obstructive pulmonary disease. Chest 2012 Oct 20, [Epub ahead of print].
10. Hatzelmann A., Morcillo E.J., Lungarella G., Adnot S., Sanjar S., Beume R., et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
11. Daliresp [package insert] 2011, Forest Pharmaceuticals, Inc, St. Louis, MO.
12. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
13. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
14. Rennard S.I., Calverley P.M., Goehring U.M., Bredenbroker D., Martinez F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
15. Lee S.D., Hui D.S., Mahayiddin A.A., Roa C.C., Kwa K.H., Goehring U.M., et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011, 16:1249-1257.
16. O'Donnell D.E., Bredenbroker D., Brose M., Webb K.A. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012, 39:1104-1112.
17. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbroker D., Bethke T.D. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
18. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161.
19. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbroker D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087.
20. Diamant Z., Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther 2011, 24:353-360.
21. Taegtmeyer A.B., Leuppi J.D., Kullak-Ublick G.A. Roflumilast-a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly 2012, 142:w13628.
22. Page C.P., Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012, 12:275-286.
23. Chong J., Poole P., Leung B., Black P.N. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, CD002309.
24. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 2011, The Cochrane Collaboration, Available from:. http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
25. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
26. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
27. Bredenbroker D., Syed J., Leichtl S., Rathgeb F., Wurst W. Roflumilast, a new, orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2002, 20(Suppl. 38):374S.
28. Boszormenyi-Nagy G., Pieters W.R., Steffen H., Timar M., Vinkler I., Teichmann P., et al. The effect of rofiumilast treatment and subsequent withdrawal in patients with COPD. Am J Respir Crit Care Med 2005, 169:A544.
29. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124.
30. Calverley P.M. Minimal clinically important difference-exacerbations of COPD. COPD 2005, 2:143-148.
31. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:19-38.
32. Jones P.W. St. George's respiratory questionnaire: MCID. COPD 2005, 2:75-79.
33. Oba Y., Lone N.A. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013, 7:13-24.
34. Vogelmeier C., Fabbri L.M., Rabe K.F., Beeh K.M., Schmidt H., Metzdorf N., et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respir Med 2013, 107:75-83.
35. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
36. Wedzicha J.A., Rabe K.F., Martinez F.J., Bredenbroker D., Brose M., Goehring U.M., et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest 2012 Nov 3, [Epub ahead of print].
37. Rutten-van Molken M.P., van Nooten F.E., Lindemann M., Caeser M., Calverley P.M. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007, 25:695-711.
38. Rabe K.F. Drug safety in COPD revisited: what is the number needed to analyzeα. Chest 2012, 142:271-274.
39. Hertel N., Kotchie R.W., Samyshkin Y., Radford M., Humphreys S., Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis 2012, 7:183-199.